Clinical trial · Observational
Home Monitoring During Chemoradiation
At-home Monitoring of Patients During Chemoradiation for Oesophageal CanceR: the AMCOR Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chemoradiotherapy is part of standard treatment for patients with locally advanced oesophageal cancer. Some patients with oesophageal cancer treated with chemoradiotherapy do not complete treatment due to toxicity, or face complications after treatment. Therefore, there is a need for better tools for assessing patients' fitness for chemoradiotherapy and to pick up early signals of deteriorating overall physical condition and complications during and after treatment to timely implement supportive care measures. Tools enabling monitoring physical activity, vital parameters and creatinine concentration in the blood at home are available but have not yet been implemented in patients undergoing chemoradiotherapy for oesophageal cancer. The feasibility and added value remain unknown.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Oesophageal Cancer | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AMCOR | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- AMCOR
- description
- Patients \>18 years with locally advanced oesophageal cancer requiring chemoradiotherapy with curative intent.
- interventionNames
- Device: AMCOR
Primary outcomes (1)
- measure
- Determine the feasibility of at home monitoring in addition to standard of care
- timeFrame
- From one week before the start of treatment until three weeks after the end of treatment
- description
- To determine the feasibility of at home monitoring in addition to standard care of patients with oesophageal cancer during chemoradiotherapy. Feasible is defined as ≥80% of measurements completed in ≥80% of the patients.
Secondary outcomes (7)
- measure
- Determine completion rates
- timeFrame
- From one week before the start of treatment until three weeks after the end of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 at the time of signing informed consent. * Histologically proven adenocarcinoma, squamous cell carcinoma or mixed type of the oesophagus or gastro-oesophageal junction. * Indication for definitive or neoadjuvant CRT, with chemotherapy that consists of weekly carboplatin/paclitaxel. * Written, informed consent. * Ability to comply with all protocol required actions (at home measurements are done individually by the participant him- or herself). Exclusion Criteria: \- Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or the carrying out of the measurements at home.
References
Publications (0)
Data not yet available